Skip to main content
. 2020 May 21;5(10):e137263. doi: 10.1172/jci.insight.137263

Figure 4. CCL5 is required for treatment efficacy.

Figure 4

(A) Three hundred thousand 4662.MD10 cells were subcutaneously implanted into C57BL/6J or B6.129P2-Ccl5tm1Hso/J (CCL5-KO) mice. Mice were treated with CD40/ICB as shown in Supplemental Figure 5A. Tumor growth kinetics shown over the course of treatment. (B) Change in tumor volume of mice from A on day 24 (or most recent available) compared with day 0. (C) Survival of mice of mice from A from each treatment group. (D) Three hundred thousand 4662.MD10 cells were subcutaneously implanted into C57BL/6J mice that were then treated with CD40/ICB and/or CCL5-blocking antibody as shown in Supplemental Figure 5B. Tumor growth kinetics shown over the course of treatment. (E) Change in tumor volume of mice from D on day 16 (or most recent available) compared with day 0. (F) Survival of mice from D from each treatment group. (A–B): n = 10 mice per group. (C): combined results of 2 identical experiments with n = 10 mice per group. (D–F): n = 10 mice per group. ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 (1-way ANOVA with Tukey’s honestly significant difference posttest in A and D; log-rank test in C and F). Data shown are representative of 2 independent experiments with 10–20 mice per group.